Asfotase alfa
From Infogalactic: the planetary knowledge core
| Clinical data | |
|---|---|
| Trade names | Strensiq |
| Legal status |
|
| Routes of administration |
Subcutaneous injection |
| Identifiers | |
| DrugBank | DB09105 |
Asfotase alfa is a drug used in the Treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia[1][2]
Asfotase alfa is manufactured by Alexion Pharmaceuticals and It was granted breakthrough therapy designation by FDA in 2015.
References
External links
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Infobox drug articles without a structure image
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- Articles containing unverified chemical infoboxes
- Pharmacology stubs
- Orphan drugs
